Xenetic Biosciences, Inc. (XBIO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
XBIO currently has 2.29M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 48.68% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 2.3M shares outstanding |
2.3M | 0 |
| Nov 12, 2025 |
10-Q filing | 2.3M shares outstanding |
2.3M | 0 |
| Aug 12, 2025 |
10-Q filing | 1.5M shares outstanding |
1.5M | 350K |
| May 13, 2025 |
10-Q filing | 1.5M shares outstanding |
1.5M | 350K |
| Mar 18, 2025 |
10-K filing | 1.5M shares outstanding |
1.5M | 350K |
| Nov 12, 2024 |
10-Q filing | 1.5M shares outstanding |
1.5M | 350K |
| Oct 21, 2024 |
S-3 filing: Xenetic Biosciences, Inc. files an S-3 to offer and sell shares of its common stock, preferred stock, warrants, units, rights, depositary shares and debt securities with an aggregate offering price not to exceed $50,000,000. |
1.5M | 360K |
| Aug 13, 2024 |
10-Q filing | 1.5M shares outstanding |
1.5M | 360K |
| May 09, 2024 |
10-Q filing | 1.5M shares outstanding |
1.5M | 360K |
| Mar 21, 2024 |
10-K filing | 1.5M shares outstanding |
1.5M | 370K |
| Nov 09, 2023 |
10-Q filing | 1.5M shares outstanding |
1.5M | 360K |
| Aug 10, 2023 |
10-Q filing | 1.5M shares outstanding |
1.5M | 370K |
| May 15, 2023 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 15,166,596 → 1,516,660 |
1.5M | 380K |
| May 11, 2023 |
10-Q filing | 15.2M shares outstanding |
15M | 3.8M |
| Mar 22, 2023 |
10-K filing | 14.2M shares outstanding |
14M | 4.7M |
| Nov 09, 2022 |
10-Q filing | 14.3M shares outstanding |
14M | 4.6M |
| Oct 12, 2022 |
8-K filing: On October 12, 2022, the Company issued 850,000 shares of its common stock to CLS Therapeutics, LLC in exchange for the assignment of certain patent rights. |
14M | 4.9M |
| Aug 11, 2022 |
10-Q filing | 14.1M shares outstanding |
14M | 4.9M |
| May 12, 2022 |
10-Q filing | 14.3M shares outstanding |
14M | 4.6M |
| Apr 27, 2022 |
8-K filing: Xenetic Biosciences, Inc. issued 375,000 shares of common stock to CLS Therapeutics LTD and OPKO Health, Inc. in connection with an Exclusive Sublicense Agreement and 500,000 shares of common stock to CLS Therapeutics LTD in connection with an Exclusive License Agreement. |
13M | 5.5M |
| Mar 22, 2022 |
10-K filing | 13.4M shares outstanding |
13M | 5.5M |
| Nov 16, 2021 |
8-K filing: Xenetic Biosciences, Inc. exchanged warrants to purchase 129,084 shares of common stock for 51,634 shares of common stock, resulting in the cancellation of all Holder's Warrants. |
13M | 5.6M |
| Nov 12, 2021 |
10-Q filing | 13.4M shares outstanding |
13M | 5.6M |
| Oct 20, 2021 |
S-3/A filing: Xenetic Biosciences, Inc. files an S-3/A registration statement to offer and sell shares of its common stock, preferred stock, warrants, units, rights, depositary shares and debt securities with an aggregate offering price not to exceed $50,000,000. |
13M | 5.8M |
| Oct 12, 2021 |
S-3 filing: Xenetic Biosciences, Inc. may offer, issue and sell shares of its common stock, preferred stock, warrants, units, rights, depositary shares and debt securities in one or more offerings. |
9.7M | 9.3M |
| Aug 13, 2021 |
S-3 filing: This S-3 filing relates to the resale or other disposition from time to time of up to (i) 950,000 shares of the Company's common stock, (ii) 4,629,630 shares of Common Stock underlying outstanding warrants with an exercise price of $3.30 per share, and (iii) 3,679,630 shares of Common Stock underlying outstanding warrants with an exercise price of $0.001 per share. |
9.7M | 9.3M |
| Aug 12, 2021 |
10-Q filing | 9.7M shares outstanding |
9.7M | 0 |
| Jul 28, 2021 |
8-K filing: Xenetic Biosciences, Inc. entered into a securities purchase agreement for a private placement of 950,000 shares of common stock, warrants to purchase 4,629,630 shares, and pre-funded warrants to purchase up to 3,679,630 shares, with gross proceeds expected to be approximately $12.5 million. ($12.5M proceeds) |
8.7M | 0 |
| May 11, 2021 |
10-Q filing | 8.7M shares outstanding |
8.7M | 0 |
| Mar 16, 2021 |
10-K filing | 8.7M shares outstanding |
8.7M | 0 |
| Dec 14, 2020 |
8-K filing: Xenetic Biosciences, Inc. completed a registered direct offering of 2,448,980 shares of common stock at a price of $2.45 per share, resulting in gross proceeds of approximately $6.0 million. ($6.0M proceeds) |
6.3M | 0 |
| Nov 12, 2020 |
10-Q filing | 6.3M shares outstanding |
6.3M | 0 |
| Aug 12, 2020 |
10-Q filing | 6.3M shares outstanding |
6.3M | 0 |
| Jun 16, 2020 |
8-K filing: Xenetic Biosciences, Inc. entered into a Master Service Agreement with PJSC Pharmsynthez to advance the development of the Company's XCART technology, with potential milestone payments including the option for Xenetic to issue up to 1,000,000 shares of common stock to Pharmsynthez upon achievement of certain milestones. |
6.3M | 0 |
| May 14, 2020 |
10-Q filing | 6.3M shares outstanding |
6.3M | 0 |
| Mar 26, 2020 |
10-K filing | 6.3M shares outstanding |
6.3M | 0 |